D.A. Davidson & CO. Sells 176,630 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

D.A. Davidson & CO. cut its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 82.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,000 shares of the biotechnology company’s stock after selling 176,630 shares during the period. D.A. Davidson & CO.’s holdings in Heron Therapeutics were worth $57,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Wealth Enhancement Advisory Services LLC grew its stake in shares of Heron Therapeutics by 21.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 7,927 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Heron Therapeutics by 456.5% in the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 84,205 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Heron Therapeutics by 18.4% during the 3rd quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 79,680 shares during the period. King Wealth Management Group lifted its position in Heron Therapeutics by 52.3% in the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Heron Therapeutics in the third quarter valued at about $72,000. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Price Performance

HRTX stock opened at $2.05 on Friday. The business’s fifty day moving average price is $1.67 and its two-hundred day moving average price is $1.71. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The stock has a market capitalization of $311.79 million, a price-to-earnings ratio of -11.39 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. Research analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on HRTX shares. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.